IRIS
MERCURIO, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.517
NA - Nord America 1.724
AS - Asia 1.298
SA - Sud America 219
AF - Africa 85
OC - Oceania 2
Totale 5.845
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.680
RU - Federazione Russa 1.079
IT - Italia 800
SG - Singapore 707
HK - Hong Kong 258
DE - Germania 194
BR - Brasile 184
CN - Cina 148
NL - Olanda 89
FI - Finlandia 71
FR - Francia 62
VN - Vietnam 48
GB - Regno Unito 39
IN - India 38
CI - Costa d'Avorio 37
CA - Canada 29
IE - Irlanda 29
JP - Giappone 21
PT - Portogallo 21
ZA - Sudafrica 20
ES - Italia 18
LT - Lituania 18
AT - Austria 17
UA - Ucraina 15
KR - Corea 13
PL - Polonia 13
BD - Bangladesh 10
BE - Belgio 10
MX - Messico 10
TR - Turchia 10
AR - Argentina 9
CO - Colombia 9
EG - Egitto 9
GE - Georgia 7
SE - Svezia 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
IQ - Iraq 6
MA - Marocco 6
VE - Venezuela 6
CZ - Repubblica Ceca 5
PK - Pakistan 5
EC - Ecuador 4
HR - Croazia 4
PH - Filippine 4
TN - Tunisia 4
UZ - Uzbekistan 4
CH - Svizzera 3
CL - Cile 3
KE - Kenya 3
RS - Serbia 3
BJ - Benin 2
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
LV - Lettonia 2
MK - Macedonia 2
NO - Norvegia 2
PE - Perù 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
DK - Danimarca 1
DZ - Algeria 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
SA - Arabia Saudita 1
SI - Slovenia 1
TG - Togo 1
TH - Thailandia 1
UY - Uruguay 1
Totale 5.845
Salva come PNG Salva come JPEG
Città #
Singapore 515
Chandler 305
Moscow 295
Hong Kong 257
Ashburn 137
Santa Clara 118
Naples 94
Millbury 71
Lawrence 67
Munich 67
Des Moines 51
Amsterdam 48
Boston 44
Napoli 40
Dong Ket 38
Milan 37
Rome 36
Hefei 29
Helsinki 29
Turku 26
Frankfurt am Main 25
Nanjing 25
Wilmington 23
Palermo 20
Seattle 20
Beijing 18
Falkenstein 18
Sennori 16
Bologna 15
Caserta 14
Fairfield 14
Nuremberg 14
Council Bluffs 13
Dallas 13
Princeton 13
Seoul 13
Shenyang 13
São Paulo 13
Bari 11
Catania 11
Kochi 10
London 10
Montijo 10
Ottawa 10
Pune 10
Turin 10
Woodbridge 10
Düsseldorf 9
Toronto 9
Bogotá 8
Chengdu 8
Dublin 8
Houston 8
Manfredonia 8
Marcianise 8
Roubaix 8
Vienna 8
Changsha 7
Hebei 7
Lappeenranta 7
Los Angeles 7
New York 7
Atlanta 6
Battipaglia 6
Brescia 6
Chennai 6
Foggia 6
Menlo Park 6
Nanchang 6
Padova 6
Sofia 6
Tbilisi 6
Wroclaw 6
Belo Horizonte 5
Brooklyn 5
Cambridge 5
Castelcovati 5
Chicago 5
Collecchio 5
Eindhoven 5
Florence 5
Johannesburg 5
Madrid 5
Redwood City 5
Rio de Janeiro 5
Tokyo 5
Ariano Irpino 4
Betim 4
Cologne 4
Dhaka 4
Grottolella 4
Hengshui 4
Kronberg 4
Leawood 4
Locorotondo 4
Oeiras 4
Olomouc 4
Osasco 4
Piemonte 4
Pisa 4
Totale 3.000
Salva come PNG Salva come JPEG
Nome #
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice 640
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 121
Antineoplastic drug-induced cardiotoxicity: A redox perspective 103
Meccanismi molecolari della cardiotossicità indotta da antracicline e radioterapia 99
Cardiac sympathetic dysfunction in pulmonary arterial hypertension: Lesson from left-sided heart failure 92
Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients 90
Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis 87
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue 87
Severe Aortic Valve Regurgitation in Relapsing Polychondritis 86
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients 86
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial 84
Adapted recreational football Small Sided Games improves cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes: results from a pilot study 84
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 82
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 82
What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients 81
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 81
New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension 80
The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department 76
Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC) 74
Oxidative stress in anticancer therapies-related cardiac dysfunction 74
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications 72
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. 70
Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment 70
Novel metrics for risk stratification with nuclear cardiology 69
Time-weighted lactate as a predictor of adverse outcome in acute heart failure 69
Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases 68
Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: A multicenter, double blind, randomized, placebo controlled trial 68
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management 68
Cardiovascular events and treatment of children with high risk medulloblastoma 67
Prevention of cardiovascular complications in elderly cancer patients 67
Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs 66
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF 66
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis 65
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 64
Mildly Elevated Pulmonary Hypertension: Gray Zone or Already a Disease? 63
Commentary on “Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fraction” 63
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 63
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure 61
Endocrine alterations are the main determinants of cardiac remodelling in restrictive anorexia nervosa 61
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors 60
Editorial: Myocardium regeneration and cardioprotection 59
Preventing antiblastic drug-related cardiomyopathy: Old and new therapeutic strategies 59
Long-term follow-up in high risk hypertensive patients with carotid dolicoarteriopathies 59
Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies 58
Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure 57
Metabolomic perspectives in antiblastic cardiotoxicity and cardioprotection 55
Prevention of cancer-therapy-related heart failure 55
Beta-blockers in pulmonary arterial hypertension: Time for a second thought? 54
Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome 53
Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors 52
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function 50
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors 50
The broad spectrum of cardiotoxicities from immunotherapies 49
Sex-related differences in COVID-19 lethality 49
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib 49
Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy 48
Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty 48
Peripheral Vascular Function in Dilated Cardiomyopathy of Different Etiology 48
Pulmonary Hypertension Induced by Anticancer Drugs 47
A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome e and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial 47
The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 47
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 46
Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors and clinical impact 45
Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements 43
Prognostic impact of diabetes in chronic and acute heart failure 43
Insulin resistance: Is it time for primary prevention? 42
Blood lactate in mild and moderate ARDS secondary to SARS COV 2 41
Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond 41
A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension 41
Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure 41
Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances 41
Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview 40
Innovations in medical therapy of heart failure with reduced ejection fraction 39
Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers 36
Cardiovascular and metabolic effects of Berberine 36
Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography 35
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better 34
Right ventricular dysfunction in chronic heart failure: clinical laboratory and echocardiographic characteristics. (the RIVED-CHF registry) 33
Causes and outcomes of {ICU} hospitalisations in patients with pulmonary arterial hypertension 33
Non-cardiovascular comorbidities in heart failure patients and their impact on prognosis 33
Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction 32
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension 32
Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension 30
Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2 29
Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension 27
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 26
Inflammation at the crossroad between cancer and heart failure 26
Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: Application of the ESC/ERS risk prediction model 25
Lung ultrasound as diagnostic tool for SARS-CoV-2 infection 25
The multifaceted mechanisms of nitroxyl in heart failure: inodilator or ‘only’ vasodilator? 25
Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature 24
Phenotyping pulmonary hypertension in systemic sclerosis: a moving target 24
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome 24
Circulating miR-10b-5p, miR-193a-3p, and miR-1-3p Are Deregulated in Patients with Heart Failure and Correlate with Hormonal Deficiencies 23
Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades 23
Essential hypertension worsens left ventricular contractility in systemic sclerosis 23
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy 22
Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis 22
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 21
Echocardiographic assessment and clinical implication of functional tricuspid regurgitation in heart failure with reduced or preserved ejection fraction (ECLIPSE-HF) : Rationale and design of the study 21
Totale 5.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021220 22 14 6 7 35 7 28 8 13 24 12 44
2021/2022432 4 0 6 14 8 12 24 31 27 29 103 174
2022/20231.018 85 67 58 79 114 88 46 130 190 86 49 26
2023/2024663 44 70 73 52 34 81 33 83 20 27 103 43
2024/20253.160 145 186 22 43 61 220 308 235 163 337 1.109 331
2025/2026222 222 0 0 0 0 0 0 0 0 0 0 0
Totale 6.055